T cell acute lymphoblastic leukemia (T-ALL) is difficult to treat when it relapses after therapy or is chemoresistant; the prognosis of patients with relapsed or refractory T-ALL is generally poor. We report a case series of 17 such patients who received autologous chimeric antigen receptor (C...
Here we demonstrate that T cells expressing TCRs specific for peptides from the intracellular lymphoid-specific enzyme terminal deoxynucleotidyl transferase (TdT), presented in the context of HLA-A*02:01, specifically eliminate primary acute lymphoblastic leukemia (ALL) cells of T- and B-cell ...
Prognostic factors in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990;77:166-73.Shuster JJ, Falletta JM, Pullen DJ, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990;75:166–173....
Protein kinase inhibitors are amongst the most successful cancer treatments, but targetable kinases activated by genomic abnormalities are rare in T cell acute lymphoblastic leukemia. Nevertheless, kinases can be activated in the absence of genetic defects. Thus, phosphoproteomics can provide information on...
[28], which influences the efficacy and safety of CAR T-cell therapy. Single-cell sequencing technologies can systematically evaluate the impact of the above factors on the final CAR T-cell product, guiding the rational design and optimization of CAR T-cell therapy. CAR is an engineered ...
The clonal expansion of primitive myeloid cells causes acute myeloid leukemia (AML). The disease shows high heterogeneity and is associated, in some cases, with poor prognosis. Although CAR-T cells are remarkably productive for treating B-cell tumors, their use for other malignancies, such as AML...
[8]Zhang M,Zhou L,Zhao H,et al.Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy[J].Clin Cancer Res,2021,27(23):6384-6392. ...
cell leukemia and lymphopoiegenesis and may function as tumor suppressor genes such as miR-451, miR-31, miR-150, and miR-29a or oncogenes such as miR-222, miR-223, miR-17–92, and miR-155. In T-cell leukemia and lymphoma, microRNA can be used as novel biomarkers for prognosis ...
It has been nearly half a century since angioimmunoblastic T-cell lymphoma (AITL) was characterized in the early 1970’s. Our understanding of the disease has dramatically changed due to multiple discoveries and insights. One of the key features of AITL
et al. Monitoring of T-cell repertoire was useful for predicting graft-versus-host disease prognosis in a patient with chronic myelogeneous leukemia after allogeneic bone marrow transplantation. Transplant. Proc. 36, 3200–3202 (2004). CAS PubMed Google Scholar Kamminga, L. M. et al. ...